| |
|
|
|
|
|
|
|||
|
Blood, Vol. 92 No. 6 (September 15), 1998:
pp. 1852-1858
RAPID COMMUNICATION
By
From the Division of Hematology, Department of Internal Medicine, and
the Blood Center, Keio University, Tokyo, Japan; the Department of
Pediatrics, University of Washington, School of Medicine, Seattle, WA;
and the Division of Hematology and Medical Oncology, Oregon Health
Sciences University, Portland, OR.
Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT)
are caused by mutations of the WAS protein (WASP) gene. All
hematopoietic stem cell-derived lineages, including platelets, express
WASP. Platelets from WAS patients are smaller than their normal
counterparts and defects in platelet aggregation and actin polymerization have been reported. To determine if WASP is important for normal platelet function, we examined its role in signal
transduction. We found that collagen but not thrombopoietin or thrombin
induces a rapid and robust increase in tyrosine phosphorylation of
platelet-associated WASP. Collagen-induced tyrosine phosphorylation of
WASP was inhibited by cytochalasin D and wortmannin, respectively,
suggesting that actin polymerization and phosphatidylinositol 3-kinase
(PI3-kinase) play a role in the induction of tyrosine phosphorylation
of WASP. Binding of glutathion S-transferase (GST)-Grb2 to WASP was
seen in the lysate of resting platelets. The binding was reduced when lysates from collagen-stimulated platelets were incubated with GST-Grb2, suggesting that tyrosine phosphorylation of WASP may directly
or indirectly modulate the adapter function of WASP. Although thrombin-
and thrombopoietin-induced increase in tyrosine phosphorylation of WASP
is negligible or marginal, WASP from thrombin-activated platelets
became incorporated into the Triton X-100-insoluble 10,000g
sedimentable residue in an aggregation-dependent manner, suggesting
that it may have a regulatory role in platelet cytoskeletal processes
during aggregation. Lastly, we found that WASP is cleaved in response
to activation of calpain, a protease that may have a role in
postaggregation signaling processes. Our data suggest that collagen
specifically induces an increase in tyrosine phosphorylation of WASP
and that WASP is involved in signaling during thrombin-induced aggregation by its redistribution to the cytoskeleton and its cleavage
during aggregation.
© 1998 by The American Society of Hematology.
MUTATIONS IN THE classic Wiskott-Aldrich
syndrome (WAS) protein (WASP) gene may result in WAS or in a
milder phenotype, X-linked thrombocytopenia (XLT).1-4
Whereas the immune defect in XLT is either mild or absent,
thrombocytopenia and platelets of small size are common features for
both phenotypes, suggesting that WASP may have a unique and essential
role in platelet production and the regulation of platelet function in
the circulation.5-8 WASP is a 64-kD protein expressed
exclusively in hematopoietic cells.9,10 Because WASP does
not have a known catalytic domain, it has been postulated that it may
serve as an adapter protein for other signaling and cytoskeletal
molecules. This possibility has been further supported by the reports
that WASP binds in vitro to several tyrosine kinases (c-Src, Fyn, Tec
family kinases, and cERG), Grb2, p47nck, and phospholipase
C Given the similarity between BCR signaling in B cells and
collagen-induced signalings in platelets, we postulated that normal platelets, which express WASP and BTK (unpublished
observation), represent a model system to investigate the
role of WASP in signal transduction.
To accomplish this, we examined whether WASP becomes uniquely tyrosine
phosphorylated after treatment with collagen. We found that
collagen-treated but not thrombin- or thrombopoietin-treated platelets
substantially increase tyrosine phosphorylation of WASP. In contrast,
thrombin induces redistribution of WASP into the Triton
X-100-insoluble residue in an aggregation-dependent fashion. Finally,
similar to many proteins incorporated into the Triton X-100-insoluble
residue after platelet aggregation, such as integrin Materials.
Prostaglandin E1 (PGE1), cytochalasin D,
wortmannin, calcium ionophore A23187, Arg-Gly-Asp-Ser (RGDS) peptide,
dibucaine, dimethyl sulfoxide (DMSO), aspirin, apyrase (type VIII),
N-2-hydroxyethylpiperazine-N Platelet preparation.
Human blood from healthy volunteers was drawn by venipuncture into 1/10
vol of 3.8% (wt/vol) trisodium citrate and gently mixed. Platelet-rich
plasma (PRP) was prepared by centrifugation of whole blood at
200g for 20 minutes. PRP was aspirated and incubated with
aspirin (2 mmol/L) for 30 minutes at room temperature. After the
addition of PGE1 (1 µmol/L) from a stock solution in
absolute ethanol (1 mmol/L), the PRP was spun at 800g to form a
soft platelet pellet. The pellet was resuspended in 1 mL of a modified
HEPES-Tyrode buffer (129 mmol/L NaCl, 8.9 mmol/L NaHCO3,
0.8 mmol/L KH2PO4, 0.8 mmol/L
MgCl2, 5.6 mmol/L dextrose, and 10 mmol/L HEPES, pH 7.4)
also containing apyrase (2 U/mL) and washed twice. Platelets were
resuspended at a concentration of 3 × 108 cells/mL in
the same buffer containing apyrase (2 U/mL) at 37°C. RGDS peptide
(200 µmol/L) was added whenever it was necessary to inhibit platelet
aggregation.
Gel electrophoresis and Western blotting to detect tyrosine
phosphorylated proteins or WASP.
Platelet stimulation was terminated by the addition of an equal volume
of 2× concentrated Laemmli's sample buffer (10% glycerol, 1%
SDS, 5% 2-mercaptoethanol, 50 mmol/L Tris-HCl [pH 6.8], and 0.002%
bromophenol blue), 10 mmol/L EGTA, and 1 mmol/L sodium orthovanadate. After boiling at 95°C for 5 minutes, one-dimensional SDS-electrophoresis was performed on 10% or 7.5% to 15%
polyacrylamide gels.24-26 Separated proteins were
electrophoretically transferred from the gel onto PVDF membranes in a
buffer containing Tris (25 mmol/L), glycine (192 mmol/L), and 20%
methanol at 0.2 amps for 12 hours at room temperature. To block
residual protein binding sites, membranes were incubated in TBST
(Tris-buffered saline [TBS]: 10 mmol/L Tris, 150 mmol/L NaCl, pH 7.6 with 0.1% Tween 20) with 10% chicken egg albumin. The blots were
washed with TBST and incubated overnight with primary antibodies at a
final concentration of 1.0 µg/mL for antibody 4G10 and 1:1,000
dilution for antibody 503 in TBST. The primary antibody was removed and
the blots were washed four times in TBST and incubated with horse
radish peroxidase-conjugated second antibody diluted 1:3,000 in TBST.
Blots were then washed four times in TBST. Antibody reactions were
detected with chemiluminescence according to the manufacturer's
instructions.
Immunoprecipitation.
Platelet stimulation was terminated by the addition of an equal amount
of lysis buffer (15 mmol/L HEPES, 150 mmol/L NaCl, 1 mmol/L
phenylmethyl sulfonyl fluoride [PMSF], 10 mmol/L EGTA, 1 mmol/L sodium orthovanadate, 0.8 µg/mL leupeptin, 2% Triton X-100
[vol/wt], pH 7.4). After 20 minutes on ice, the lysates were
centrifuged at 10,000g (at 4°C) for 20 minutes. The
supernatant was removed, incubated with protein A-Sepharose (40 µL of
50% slurry) for 1 hour, and centrifuged to obtain the precleared
supernatant. The anti-WASP polyclonal antibody 503 was then added and
the mixtures were incubated for 2 to 3 hours on ice (concentration, 2 µL/mL supernatant). Protein A-Sepharose (40 µL of 50% slurry/mL
supernatant) was added and incubated for several hours. The immune
complexes were washed with 1 mL of cold washing buffer (the same as the lysis buffer except the concentration of Triton X-100 [vol/wt] was
1%) three times and then resuspended in Laemmli's sample buffer.
Isolation of platelet cytoskeleton.
The Triton X-100-insoluble cytoskeleton was isolated as
described,25,26 with the following
modification. An equal amount of lysis buffer was added to
platelet suspensions to solubilize platelets. After 5 minutes on ice,
the lysates were centrifuged at 10,000g. The resulting pellet
was washed twice in washing buffer. For one-dimensional SDS
electrophoresis, the Triton X-100-insoluble residue was solubilized in
SDS sample buffer. The supernatant was diluted with an equal volume of
2× concentrated SDS sample buffer.
Collagen-induced tyrosine phophorylation of WASP.
Platelets suspended in the presence of 200 µmol/L RGDS peptide were
treated with either collagen (50 µg/mL), thrombin (1 U/mL), or
thrombopoietin (100 ng/mL). After incubation for various times, the
platelets were lysed and the lysates were incubated with anti-WASP antiserum 503 and protein A Sepharose. The same amount of
a 64-kD protein recognized by the anti-WASP antiserum was
immunoprecipitated from all cellular lysates in each set of experimemts
(Fig 1A through D, lower panels). After
treatment with collagen, WASP was increasingly tyrosine phosphorylated
over the low basal level (Fig 1A, upper panel). Tyrosine
phosphorylation reached a plateau within 2 minutes. In contrast,
thrombin and thrombopoietin induced a marginal increase in tyrosine
phosphorylation of WASP in platelets (Fig 1B and C), but the degree of
phosphorylation by either of the reagents was much smaller than that
induced by collagen. When platelet suspensions were stirred in the
absence of RGDS peptide, thrombin-induced increase in tyrosine
phosphorylation of WASP was still minimal (Fig 1D).
Collagen-induced tyrosine phosphorylation was inhibited by
cytochaslsin D and wortmannin.
Because of recent reports suggesting a role of WASP in the
initiation of actin polymerization in platelets27 as well
as in T cells28 and because of evidence that PI3-kinase is
also involved in the regulation of cytoskeletal reorganization of
platelets,29,30 we examined the effects of cytochalasin D
(an inhibitor of actin polymerization) and wortmannin (a PI3-kinase
inhibitor) on WASP tyrosine phosphorylation. Platelets were treated
with 0.1% DMSO (the vehicle for cytochalasin D and wortmannin) for 30 minutes, cytochalasin D (10 µmol/L) for 10 minutes, or wortmannin (50 nmol/L) for 30 minutes. Cytochalasin D or wortmannin but not DMSO
inhibited the collagen-induced increase in tyrosine phosphorylation of
WASP (Fig 2).
WASP associates with the cytoskeleton after platelet aggregation.
We next examined the possibility that WASP plays a role in signaling
after platelet aggregation. Because it has been shown that many
signaling molecules, including c-Src, become incorporated into the
integrin-rich cytoskeleton after platelet
aggregation,25,26,31-33 we tested the possibility that WASP
may be incorporated into the cytoskeleton. In resting platelets, WASP
was found predominantly in Triton X-100-soluble fraction
(Fig 3). However, after stimulation of
platelets by adding thrombin and stirring to induce platelet aggregation, WASP became associated with the Triton X-100-insoluble residue. This association of WASP with the cytoskeleton was inhibited by omitting stirring to minimize platelet aggregation (lane 6, Fig 3),
as has been reported for c-Src, Vav, Crkl, Grb2, c-Cbl, and
Binding of GST-Grb2 but not GST to WASP.
Because WASP is thought to function as an adapter protein in
lymphocytes, we next asked whether WASP in platelets may also bind to
other proteins and, if so, whether collagen-induced stimulation may
affect the adapter function of WASP. Because it is impossible to
examine all SH2/SH3 proteins expressed in platelets for binding to
WASP,25,26,31-33 we focused our attention on Grb2, which is known to be constitutively associated with WASP in
lymphocytes.10,12 Platelet lysates obtained before and 5 minutes after collagen stimulation were equally divided for
immunoprecipitation with anti-WASP antiserum or for GST-fusion
protein-binding studies. WASP was immunoprecipitated by WASP antiserum
503 but not by the preimmune serum from both lysates equally well (data
not shown), confirming that the lysates have the same amount of WASP.
As expected, tyrosine phosphorylation of the 64-kD protein in platelets
was dramatically increased after collagen stimulation (data not shown). The 64-kD tyrosine phosphorylated protein was not precipitated by
preimmune serum. GST-Grb2 but not GST on agarose precipitated WASP from
the same lysates (Fig 5). The amount of
WASP precipitated by GST-Grb2 on agarose was significantly reduced when
lysates from collagen-stimulated platelets were used (Fig 5, lane 2).
Although platelet abnormalities are a hallmark of WAS, the role of WASP
in platelet release and function is not
understood.5-8,27,28 Because of reports that, in other
cells, WASP may serve as an adapter protein for other molecules
involved in signaling or cytoskeletal reorganization, we explored
signal transduction in human platelets and found that collagen, a
natural agonist for platelets, is a strong inducer of tyrosine
phosphorylation of WASP. Because WASP is believed to be an adapter-like
molecule and protein tyrosine phosphorylation is essential for
collagen-induced platelet activation,20-23 it is tempting
to speculate that the induction of tyrosine phosphorylation of WASP is
generating the potential binding site(s) for proteins containing SH2
and/or PTB domains, thus contributing to collagen-induced signaling in platelets. The robust induction of tyrosine
phosphorylation of WASP seems to be a unique response to
collagen-induced stimulation, because exposure to thrombin or
thrombopoietin resulted in only a small increase in tyrosine
phosphorylation of WASP. The observation that tyrosine phosphorylation
of WASP during thrombin-induced platelet aggregation was also marginal
may be misleading, being caused by the artificial dephosphorylation
during the lysis of platelet aggregates, as has been reported by Law et
al39 for integrin Submitted April 3, 1998;
accepted June 26, 1998.
1.
Derry JM,
Ochs HD,
Francke U:
Isolation of a novel gene mutated in Wiskott-Aldrich syndrome.
Cell
78:635,
1994[Medline]
[Order article via Infotrieve]
2.
Kwan SP,
Hagemann TL,
Radtke BE,
Blaese RM,
Rosen FS:
Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene.
Proc Natl Acad Sci USA
92:4706,
1995
3.
Zhu Q,
Zhang M,
Blaese RM,
Derry JM,
Junker A,
Francke U,
Chen SH,
Ochs HD:
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Blood
86:3797,
1995
4.
Kolluri R,
Shehabeldin A,
Peacocke M,
Lamhonwah AM,
Teichert-Kuliszewska K,
Weissman SM,
Siminovitch KA:
Identification of WASP mutations in patients with Wiskott-Aldrich syndrome and isolated thrombocytopenia reveals allelic heterogeneity at the WAS locus.
Hum Mol Genet
4:1119,
1995
5.
Ochs HD,
Slichter SJ,
Harker LA,
Von Behrens WE,
Clark RA,
Wedgwood RJ:
The Wiskott-Aldrich syndrome: Studies of lymphocytes, granulocytes, and platelets.
Blood
55:243,
1980
6.
White JG,
Gerrard JM:
Ultrastructural features of abnormal blood platelets. A review.
Am J Pathol
83:589,
1976[Medline]
[Order article via Infotrieve]
7.
Sullivan KE:
Genetic and clinical advances in Wiskott-Aldrich syndrome.
Curr Opin Pediatr
7:683,
1995[Medline]
[Order article via Infotrieve]
8.
Bellucci S:
Megakaryocytes and inherited thrombocytopenias.
Clin Haematol
10:149,
1997
9.
Zhu Q,
Watanabe C,
Liu T,
Hollenbaugh D,
Blaese RM,
Kanner SB,
Aruffo A,
Ochs HD:
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.
Blood
90:2680,
1997
10.
Stewart DM,
Treiber-Held S,
Kurman CC,
Facchetti F,
Notarangelo LD,
Nelson DL:
Studies of the expression of the Wiskott-Aldrich. syndrome protein.
J Clin Invest
97:2627,
1996[Medline]
[Order article via Infotrieve]
11.
Banin S,
Truong O,
Katz DR,
Waterfield MD,
Brickell PM,
Gout I:
Wiskott-Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases.
Curr Biol
6:981,
1996[Medline]
[Order article via Infotrieve]
12.
Cory GO,
MacCarthy-Morrogh L,
Banin S,
Gout I,
Brickell PM,
Levinsky RJ,
Kinnon C,
Lovering RC:
Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.
J Immunol
157:3791,
1996[Abstract]
13.
Kinnon C,
Cory GO,
MacCarthy-Morrogh L,
Banin S,
Gout I,
Lovering RC,
Brickell PM:
The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways.
Biochem Soc Trans
25:648,
1997[Medline]
[Order article via Infotrieve]
14.
Finan PM,
Soames CJ,
Wilson L,
Nelson DL,
Stewart DM,
Truong O,
Hsuan JJ,
Kellie S:
Identification of regions of the Wiskott-Aldrich syndrome protein responsible for association with selected Src homology 3 domains.
J Biol Chem
271:26291,
1996
15.
Bunnell SC,
Henry PA,
Kolluri R,
Kirchhausen T,
Rickles RJ,
Berg LJ:
Identification of Itk/Tsk Src homology 3 domain ligands.
J Biol Chem
271:25646,
1996
16.
Rivero-Lezcano OM,
Marcilla A,
Sameshima JH,
Robbins KC:
Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains.
Mol Cell Biol
15:5725,
1995[Abstract]
17.
Pawson T,
Scott JD:
Signaling through scaffold, anchoring, and adaptor proteins.
Science
278:2075,
1997
18.
Margolis B:
The PI/PTB domain: A new protein interaction domain involved in growth factor receptor signaling.
J Lab Clin Med
128:235,
1996[Medline]
[Order article via Infotrieve]
19.
Birge RB,
Knudsen BS,
Besser D,
Hanafusa H:
SH2 and SH3-containing adaptor proteins: Redundant or independent mediators of intracellular signal transduction.
Genes Cells
1:595,
1996[Abstract]
20.
Tsuji M,
Ezumi Y,
Arai M,
Takayama H:
A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets.
J Biol Chem
272:23528,
1997
21.
Gibbins JM,
Okuma M,
Farndale R,
Barnes M,
Watson SP:
Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain.
FEBS Lett
413:255,
1997[Medline]
[Order article via Infotrieve]
22.
Polgar J,
Clemetson JM,
Kehrel BE,
Wiedemann M,
Magnenat EM,
Wells TNC,
Clemetson KJ:
Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor.
J Biol Chem
272:13576,
1997
23.
Poole A,
Gibbins JM,
Turner M,
van Vugt MJ,
van de Winkel JG,
Saito T,
Tybulewicz VL,
Watson SP:
The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen.
EMBO J
16:2333,
1997[Medline]
[Order article via Infotrieve]
24.
Frangioni JV,
Oda A,
Smith M,
Salzman EW,
Neel BG:
Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets.
EMBO J
12:4843,
1993[Medline]
[Order article via Infotrieve]
25.
Oda A,
Miyakawa Y,
Druker BJ,
Ishida A,
Ozaki K,
Ohashi H,
Wakui M,
Handa M,
Watanabe K,
Okamoto S,
Ikeda Y:
Crkl is constitutively tyrosine phopshorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphoryalted in normal platelets stimulated by thrombopoietin.
Blood
88:4303,
1996
26.
Miyakawa Y,
Oda A,
Druker BJ,
Ozaki K,
Handa M,
Ohashi H,
Ikeda Y:
Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets.
Blood
89:2789,
1997
27.
Semple JW,
Siminovitch KA,
Mody M,
Milev Y,
Lazarus AH,
Wright JF,
Freedman J:
Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure.
Br J Haematol
97:747,
1997[Medline]
[Order article via Infotrieve]
28.
Gallego MD,
Santamaria M,
Pena J,
Molina IJ:
Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation.
Blood
90:3089,
1997
29.
Rittenhouse SE:
Phosphoinositide 3-kinase activation and platelet function.
Blood
88:4401,
1996
30.
Hartwig JH,
Kung S,
Kovacsovics T,
Janmey PA,
Cantley LC,
Stossel TP,
Toker A:
D3 phosphoinositides and outside-in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate.
J Biol Chem
271:32986,
1996
31.
Clark EA,
Shattil SJ,
Brugge JS:
Regulation of protein tyrosine kinases in platelets.
Trends Biochem Sci
19:464,
1994[Medline]
[Order article via Infotrieve]
32.
Clark EA,
Brugge JS:
Integrins and signal transduction pathways: The road taken.
Science
268:233,
1995
33.
Fox JEB:
Transmembrane signaling across the platelet integrin glycoprotein IIb-IIIa.
Ann NY Acad Sci
714:75,
1994[Abstract]
34.
Suzuki K,
Saido TC,
Hirai S:
Modulation of cellular signals by calpain.
Ann NY Acad Sci
674:218,
1992[Abstract]
35.
Oda A,
Druker BJ,
Ariyoshi H,
Smith M,
Salzman EW:
pp60src is an endogenous substrate for calpain in human blood platelets.
J Biol Chem
268:12603,
1993
36.
Du X,
Saido TC,
Tsubuki S,
Indig FE,
Williams MJ,
Ginsberg MH:
Calpain cleavage of the cytoplamic domain of the integrin
37.
Tsujinaka T,
Kajiwara Y,
Kambayashi J,
Sakon M,
Higuchi N,
Tanaka T,
Mori T:
Synthesis of a new cell penetrating calpain inhibitor (calpeptin).
Biochem Biophys Res Commun
153:1201,
1988[Medline]
[Order article via Infotrieve]
38.
Wencel-Drake JD,
Okita JR,
Annis DS,
Kunicki TJ:
Activation of calpain I and hydrolysis of calpain substrates (actin-binding protein, glycoprotein Ib, and talin) are not a function of thrombin-induced platelet aggregation.
Arteriosclerosis Thromb
11:882,
1991
39.
Law DA,
Nannizzi-Alaimo L,
Phillips DR:
Outside-in integrin signal transduction.
40.
Raja S,
Avraham S,
Avraham H:
Tyrosine phosphorylation of the novel protein-tyrosine kinase RAFTK during an early phase of platelet activation by an integrin glycoprotein IIb-IIIa-independent mechanism.
J Biol Chem
272:10941,
1997
41.
Laffargue M,
Monnereau L,
Tuech J,
Ragab A,
Ragab-Thomas J,
Payrastre B,
Raynal P,
Chap H:
Integrin-dependent tyrosine phoshorylation and cytoskeletal translocation of Tec in thrombin-activated platelets.
Biochem Biophys Res Commun
238:247,
1997[Medline]
[Order article via Infotrieve]
42.
Symons M,
Derry JM,
Karlak B,
Jiang S,
Lemahieu V,
Mccormick F,
Francke U,
Abo A:
Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization.
Cell
84:723,
1996[Medline]
[Order article via Infotrieve]
43.
Kolluri R,
Tolias KF,
Carpenter CL,
Rosen FS,
Kirchhausen T:
Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42.
Proc Natl Acad Sci USA
93:5615,
1996
44.
Ramesh N,
Anton IM,
Hartwig JH,
Geha RS:
WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells.
Proc Natl Acad Sci USA
94:14671,
1997
45.
Oda A,
Ozaki K,
Druker BJ,
Miyakawa Y,
Miyazaki H,
Handa M,
Morita H,
Ohashi H,
Ikeda Y:
p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin.
Blood
88:1330,
1996
46.
Marone G,
Albini F,
di Martino L,
Quattrin S,
Poto S,
Condorelli M:
The Wiskott-Aldrich syndrome: Studies of platelets, basophils and polymorphonuclear leucocytes.
Br J Haematol
62:737,
1986[Medline]
[Order article via Infotrieve]
47.
Remold-O'Donnell E,
Van Brocklyn J,
Kenney DM:
Effect of platelet calpain on normal T-lymphocyte CD43: Hypothesis of events in the Wiskott-Aldrich syndrome.
Blood
79:1754,
1992
48.
Schoenwaelder SM,
Yuan Y,
Cooray P,
Salem HH,
Jackson SP:
Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin alphaIIbbeta3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots.
J Biol Chem
272:1694,
1997
49.
Wu Y,
Spencer SD,
Lasky LA:
Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein.
J Biol Chem
273:5765,
1998 This article has been cited by other articles:
|